Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Operating Margin (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Operating Margin for 5 consecutive years, with 82.2% as the latest value for Q4 2025.

  • On a quarterly basis, Operating Margin rose 1642.0% to 82.2% in Q4 2025 year-over-year; TTM through Dec 2025 was 101.19%, a 10285.0% increase, with the full-year FY2025 number at 101.19%, up 10284.0% from a year prior.
  • Operating Margin was 82.2% for Q4 2025 at Rhythm Pharmaceuticals, up from 102.64% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 523.15% in Q4 2022 to a low of 98280.0% in Q1 2021.
  • A 5-year average of 6421.27% and a median of 218.89% in 2023 define the central range for Operating Margin.
  • Peak YoY movement for Operating Margin: skyrocketed 9476258bps in 2022, then plummeted -69343bps in 2023.
  • Rhythm Pharmaceuticals' Operating Margin stood at 2806.22% in 2021, then skyrocketed by 119bps to 523.15% in 2022, then plummeted by -133bps to 170.28% in 2023, then skyrocketed by 42bps to 98.63% in 2024, then grew by 17bps to 82.2% in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Operating Margin are 82.2% (Q4 2025), 102.64% (Q3 2025), and 93.39% (Q2 2025).